VistaGen Therapeutics
VTGN
14 hedge funds and large institutions have $2.79M invested in VistaGen Therapeutics in 2017 Q3 according to their latest regulatory filings, with 2 funds opening new positions, 2 increasing their positions, 1 reducing their positions, and 2 closing their positions.
100% more repeat investments, than reductions
Existing positions increased: 2 | Existing positions reduced: 1
21% more capital invested
Capital invested by funds: $2.3M → $2.79M (+$481K)
0.1% more ownership
Funds ownership: 0.44% → 0.54% (+0.1%)
0% more funds holding
Funds holding: 14 → 14 (0)
0% more first-time investments, than exits
New positions opened: 2 | Existing positions closed: 2
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SFM
Sphera Funds Management
Tel Aviv,
Israel
|
+$903K |
| 2 |
Citadel Advisors
Miami,
Florida
|
+$23.5K |
| 3 |
BC
Bartlett & Co
Cincinnati,
Ohio
|
+$17.5K |
| 4 |
Vanguard Group
Malvern,
Pennsylvania
|
+$6.53K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SM
Sabby Management
Miami Beach,
Florida
|
-$48K |
| 2 |
UBS Group
Zurich,
Switzerland
|
-$10.4K |
| 3 |
TRCT
Tower Research Capital (TRC)
New York
|
-$1K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
SFM
1
Sphera Funds Management
Tel Aviv,
Israel
| $1.69M | +$903K | +17,143 | +95% |
|
2
Parallax Volatility Advisers
San Francisco,
California
| $441K | – | – | – |
|
|
NC
3
Nexthera Capital
New York
| $221K | – | – | – |
|
|
DADC
4
D.A. Davidson & Co
Great Falls,
Montana
| $157K | – | – | – |
|
|
LTFS
5
Ladenburg Thalmann Financial Services
Miami,
Florida
| $72K | – | – | – |
|
|
6
Vanguard Group
Malvern,
Pennsylvania
| $65K | +$6.53K | +124 | +10% |
|
7
Geode Capital Management
Boston,
Massachusetts
| $48K | – | – | – |
|
8
HighTower Advisors
Chicago,
Illinois
| $32K | – | – | – |
|
|
9
Citadel Advisors
Miami,
Florida
| $21K | +$23.5K | +446 | New |
|
10
Northern Trust
Chicago,
Illinois
| $17K | – | – | – |
|
|
BC
11
Bartlett & Co
Cincinnati,
Ohio
| $16K | +$17.5K | +333 | New |
|
|
HFM
12
Hartford Financial Management
Hartford,
Connecticut
| $2K | – | – | – |
|
|
SM
13
Sabby Management
Miami Beach,
Florida
| – | -$48K | -851 | Closed |
|
|
14
UBS Group
Zurich,
Switzerland
| – | -$10.4K | -197 | -97% |
|
|
TRCT
15
Tower Research Capital (TRC)
New York
| – | -$1K | -19 | Closed |
|
VTGN Hedge Fund Activity: Q3 2017 in Review
14 of the 4,011 institutional investors tracked by Wall St. Rank reported a position in VistaGen Therapeutics (VTGN) for Q3 2017, worth a combined $2.79M — up 21% from $2.3M a quarter earlier.
Fund positioning in VTGN was balanced in Q3 2017: 2 funds opened new positions, 2 closed out, 2 added to existing stakes and 1 trimmed.
The largest buyer was Sphera Funds Management, adding an estimated $903K. The largest seller was Sabby Management, exiting entirely with an estimated $48K sold.
- 14 institutional investors held VistaGen Therapeutics (VTGN) as of Q3 2017, unchanged from Q2 2017.
- Funds reported $2.79M of VistaGen Therapeutics stock for Q3 2017, up 21% quarter-over-quarter.
- 2 funds opened new VistaGen Therapeutics positions in Q3 2017 and 2 closed out, a net change of 0 holders.
- The largest VistaGen Therapeutics buyer in Q3 2017 was Sphera Funds Management, an estimated $903K added.
- The largest VistaGen Therapeutics seller in Q3 2017 was Sabby Management, an estimated $48K sold.
Based on aggregated 13F filings for Q3 2017.